✦ LIBER ✦

CORRELATES OF DISSATISFACTION WITH TREATMENT IN PATIENTS WITH PROSTATE CANCER DIAGNOSED THROUGH SCREENING

✍ Scribed by CARVALHAL, GUSTAVO F.; SMITH, DEBORAH S.; RAMOS, CHRISTIAN; KRYGIEL, JULIE; MAGER, DOUGLAS E.; YAN, YAN; CATALONA, WILLIAM J.

Book ID: 122930147
Publisher: Lippincott Williams and Wilkins
Year: 1999
Tongue: English
Weight: 729 KB
Volume: 162
Category: Article
ISSN: 0022-5347
DOI: 10.1097/00005392-199907000-00027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Health-related quality of life in patien

✍ J.B. Madalinska; M.L. Essink-Bot; H.J. de Koning; W.J. Kirkels; P.J. van der Maa 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 2 views

124 OUTCOMES OF MEN DIAGNOSED WITH SCREE

124 OUTCOMES OF MEN DIAGNOSED WITH SCREEN-DETECTED PROSTATE CANCER INITIALLY WITHHOLDING RADICAL TREATMENT

✍ van den Bergh, Roderick; van Leeuwen, Pim; Wolters, Tineke; Bangma, Chris; Roobo 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 47 KB

Missed Diagnoses in Patients with Gastri

Missed Diagnoses in Patients with Gastric Cancer in Endoscopic Screening

✍ Hye Kyung Song 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Periprostatic fat correlates with tumour

Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients

✍ Joep G.H. van Roermund; Karel A. Hinnen; Christine J. Tolman; Gijsbert H. Bol; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB

CAUSES OF DEATH IN PATIENTS WITH SCREEN-

CAUSES OF DEATH IN PATIENTS WITH SCREEN-DETECTED PROSTATE CANCER

✍ Roehl, Kimberly A; Suarez, Brian K; Catalona, William J 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 60 KB

Treatment of newly diagnosed metastatic

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

✍ Gerald P. Murphy; Sunmolu Beckley; Mark F. Brady; T. Ming Chu; Jean B. Dekernion 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

by the National Prostatic Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m2 iv every three weeks, or cyclophosphamide 1 g/m2 iv every three weeks plus es